Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor and vasopeptidase inhibitor-associated angioedema

Abstract

Deficiencies in certain physiological pathways are linked with ACE or vasopeptidase inhibitor associated angioedema. Additionally, detection and/or measurement of dipeptidyl peptidase IV (DPP IV) enzyme activity and aminopeptidase P (APP) enzyme activity is a predictor of this risk. The present invention provides biological markers, diagnostic tests, and pharmaceutical indications that are useful in the diagnosis and treatment of angioedema and in the marketing and safety of certain medications. This ability can be important for the treatment of a subject that is in need of or are taking an angiotensin-converting enzyme (ACE) inhibitor and/or a vasopeptidase inhibitor (combined ACE and neutral endopeptidase (NEP) inhibitor), which are commonly used in the treatment of hypertension (high blood pressure), diabetes, and cardiac and renal diseases.

1 - 34 . (canceled)  
     
     
         35 . A method of marketing a vasopeptidase inhibitor comprising providing information about a diagnostic test adapted to identify a subject that is susceptible to angioedema as a result of taking the vasopeptidase inhibitor during a course of treatment comprising administering one of an ACE inhibitor and a vasopeptidase inhibitor.  
     
     
         36 . The method of  claim 35 , wherein the vasopeptidase inhibitor comprises an angiotensin-converting enzyme inhibitor.  
     
     
         37 . The method of  claim 35 , wherein the vasopeptidase inhibitor comprises a neutral endopeptidase inhibitor.  
     
     
         38 . The method of  claim 35 , wherein the diagnostic test comprises detecting dipeptidyl peptidase IV activity in a biological sample derived from the subject.  
     
     
         39 . The method of  claim 35 , wherein the diagnostic test comprises detecting aminopeptidase P activity in a biological sample derived from the subject.  
     
     
         40 . The method of  claim 35 , wherein the subject is a human.